Columbia Engineering neuroscientists identified a specific neural mechanism in the human brain that tags information with emotional associations for enhanced memory. The team demonstrated that high-frequency brain waves in the amygdala, a hub for emotional processes, and the hippocampus, a hub for memory processes, are critical to enhancing memory for emotional stimuli. Disruptions to this neural mechanism, brought on either by electrical brain stimulation or depression, impair memory specifically for emotional stimuli.
APRINOIA Therapeutics Inc. ("APRINOIA"), a clinical-stage biotechnology company focused on neurodegenerative diseases such as Alzheimer's Disease ("AD") and Progressive Supranuclear Palsy ("PSP"), and Ross Acquisition Corp II (NYSE: ROSS, ROSS.U, ROSS WS) ("ROSS"), a special purpose acquisition company founded by former Commerce Secretary Wilbur Ross, today announced that they have entered into a definitive agreement (the "Business Combination Agreement") for a business combination (the "Business Combination").
Also evokes central and peripheral pro-inflammatory responses
Inspiration strikes when you least expect it. For Wei Jiang, M.D., a professor of Microbiology and Immunology at the Medical University of South Carolina (MUSC), inspiration came in 2018 on a smoke-filled boat tour around Amsterdam during an international conference.
In the past decade, researchers have begun to appreciate the importance of a two-way communication that occurs between microbes in the gastrointestinal tract and the brain, known as the gut–brain axis.
The U.S. Food and Drug Administration (FDA) recently granted approval to Lecanemab, the first Alzheimer’s disease treatment to win approval since the largely failed rollout of Aduhelm two years ago.
Gut bacteria can influence brain health, according to a study of mice genetically predisposed to develop Alzheimer’s-like brain damage. The study, by researchers at Washington University School of Medicine in St. Louis, indicates that gut bacteria produce compounds that influence the behavior of immune cells, including ones in the brain that can cause neurodegeneration. The findings suggest a new approach to treating Alzheimer’s and other neurodegenerative diseases.
With falls causing millions of injuries in older adults each year, it is an increasingly important public health concern.
Six minutes of high-intensity exercise could extend the lifespan of a healthy brain and delay the onset of neurodegenerative disorders, such as Alzheimer's disease and Parkinson's disease.
The Alzheimer’s Drug Discovery Foundation (ADDF) and Harrington Discovery Institute at University Hospitals in Cleveland have granted an ADDF-Harrington Scholar Award to Christiane Wrann, PhD, DVM, Associate Professor in Medicine at the Cardiovascular Research Center and the McCance Center for Brain Health at Massachusetts General Hospital and the Harvard Medical School in Boston. Dr. Wrann will receive funding and drug development guidance to help advance her research towards potential new therapies for patients suffering from Alzheimer’s disease.
A smart intraocular lens that can be inserted into the eye to diagnose Alzheimer's has been developed for the first time in Korea.
Findings highlight potential benefit of hearing aid use
In Journal of Applied Physics, researchers present a special silicon nitride nanopore-based sensing device that is designed to provide volume information about tau and tubulin protein molecules and their aggregation states. To create the sensor, the team explored how the proteins change the current and voltage flowing through a nanopore system.
The U.S. Food and Drug Administration is poised to make a decision on another new Alzheimer’s disease treatment this week, and experts from the Jona Goldrich Center for Alzheimer’s and Memory Disorders at Cedars-Sinai are available to explain how the drug works and which patients could benefit from the medication.
For the sixth year in a row, the MIND diet has been recognized as a Best Diet for 2023 by U.S. News & World Report.
Young children sometimes believe that the moon is following them, or that they can reach out and touch it.
African Americans and Hispanics face higher risk for Alzheimer’s disease than whites in the United States, but the reason may not be solely race or ethnicity, new research shows. Instead, those minority groups are more vulnerable because of lifelong inequities in socioeconomic factors such as income, health insurance, and access to medical care that lead to an accumulation of vascular risk factors in midlife and late life, including diabetes, hypertension, and obesity.
The medical community has never researched the simultaneous impact of post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), and genetic risk factors in a large cohort … until now.
Middle-aged smokers are far more likely to report having memory loss and confusion than nonsmokers, and the likelihood of cognitive decline is lower for those who have quit, even recently, a new study has found.
Here are some of the latest articles that have been added to the Winter Holidays channel on Newswise.
Rising to meet the formidable challenge of the timely diagnosis of dementia, research scientists from Regenstrief Institute, IUPUI and the medical schools of Indiana University and University of Miami are conducting the Digital Detection of Dementia study, a real-world evaluation of the use of an artificial intelligence (AI) tool they developed for early identification of Alzheimer’s disease and related dementias in primary care, the setting where most adults receive healthcare.
A brief roundup of news and story ideas from the experts at UCLA Health.
A recent study from the University of Eastern Finland shows that previous traumatic brain injury may potentially affect the risk of frontotemporal dementia.
Led by researchers from the University of California at Irvine, a new study reveals that a long-lived Chilean rodent, called Octodon degus (degu), is a useful and practical model of natural sporadic Alzheimer’s Disease.
A recent study by researchers from the NUS Yong Loo Lin School of Medicine and the Memory, Ageing and Cognition Centre under the National University Health System revealed that low levels of ergothioneine in blood plasma may predict an increased risk of cognitive impairment and dementia, suggesting possible therapeutic or early screening measures for cognitive impairment and dementia in the elderly.
Researchers at UC San Diego provide new insights into the pathology of limbic predominate age-related TDP-43 encephalopathy, which mimics Alzheimer’s, making it very difficult to identify in living patients.
The Carol and Gene Ludwig Center for Research on Neurodegeneration will bring novel approaches to Alzheimer’s and other neurodegenerative disease research.
Alzheimer’s disease (AD) is the fifth leading cause of death in adults over 65 years old. While many potential treatments for the neurodegenerative disease focus on developing drugs to target key culprits, a relatively new approach aims to more directly treat the brain.
As human lifespans increase, so does general memory impairment – calling for the need to expand research for dementia treatment. The key to this expansion is the center focus of the SLAS Discovery featured article, “A neuronal cell-based reporter system for monitoring the activity of HDAC2” by Unemura, et al.
Early Alzheimer’s Diagnostics LLC was awarded a highly competitive NSF Small Business Technology Transfer grant. It will be used to advance the commercialization of a screening tool that tests saliva for the detection of early and preclinical Alzheimer’s disease.
For the first time, scientists have recorded human nerve cells firing together in flexible assemblies, a process that appears necessary to successfully encode long-term memories, a study led by UT Southwestern researchers reports.
The University of Kentucky is a site for the groundbreaking AHEAD study, the first-ever clinical trial to test the effect of lecanemab (investigational antibody) in people who have no cognitive symptoms of Alzheimer’s disease (AD), but in whom biomarker tests indicate amyloid is present in the brain, known as “preclinical” AD.
Investigators at Albert Einstein College of Medicine, Montefiore Health System, Regenstrief Institute, and Indiana University School of Medicine have received an $11 million grant from the National Institutes of Health (NIH) to evaluate an Einstein-developed test for assessing cognitive impairment and dementia.
New research suggests that former professional football players may face accelerated aging, despite past research showing they have life spans similar or longer than the general population In the new study, retired football players reported shorter health spans — defined as years free of disease – than men in the general population Two age-related diseases — arthritis and dementia — were found more commonly among former football players, compared with men of the same age in the general population Additionally, hypertension and diabetes were more common among younger former players, those ages 25 to 29, compared with same-age men from the general population. The results warrant further study to define the biochemical, cellular, and physiologic mechanisms behind premature aging in former football players
Researchers at Tufts University have completed the first study examining levels of vitamin D in brain tissue, specifically in adults who suffered from varying rates of cognitive decline. They found that members of this group with higher levels of vitamin D in their brains had better cognitive function.
A Rutgers expert on elder care explains how families can make the most of the season when caring for someone experiencing memory loss
Regenstrief Institute Research Scientist April Savoy, PhD, a human factors engineer and health services researcher, is developing and testing user-friendly health information tools and technology designed to enhance accessibility and value to older adults with both diabetes and Alzheimer’s disease, and their caregivers.
Here are some of the latest articles that have been added to the Behavioral Science channel on Newswise, a free source for journalists.
Researchers can detect small "toxic" aggregates of a particular protein in the blood of individuals with Alzheimer's disease and in individuals who showed no signs of cognitive impairment at the time the blood sample was taken, but who developed it at a later date.
A pair of early stage clinical studies testing the safety and efficacy of 40Hz sensory stimulation to treat Alzheimer’s disease has found that the potential therapy was well tolerated, produced no serious adverse effects and was associated with some significant neurological and behavioral benefits among a small cohort of participants.
A new study have identified which blood tests are best at detecting Alzheimer’s disease during the earliest stages, and another blood test that is optimal for detecting relevant treatment effects.
When the U.S. Food and Drug Administration gave controversial accelerated approval to the first Alzheimer’s drug in nearly 20 years, it had a surprising impact on attitudes about research into the disease.
Some people report a decline in their memory before any decline is large enough to show up on standard tests. This experience, called subjective cognitive decline, is associated with an increased risk of later developing dementia in white, Black and Latino people, according to a study published in the November 30, 2022, online issue of Neurology®, the medical journal of the American Academy of Neurology.
New research findings published in Science Advances (November 2022), help explain the progression of Alzheimer-related dementia in each patient. The findings outline a biological classification system that predicts disease severity.
Inflammatory response linked to amyloid plaque buildup
Irvine, Calif., Nov. 29, 2022 — When the U.S. Food and Drug Administration gave controversial accelerated approval to the first Alzheimer’s drug in nearly 20 years, it had a surprising impact on attitudes about research into the disease. A survey by University of California, Irvine neuroscientists has found news coverage of the FDA’s decision made the public less willing to volunteer for Alzheimer’s pharmaceutical trials.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
